Key facts
- Zealand Pharma's shares fell 20% in Copenhagen trading.
- The decline was attributed to users discontinuing the weight-loss drug.
- Gastrointestinal issues were cited as the reason for discontinuation.
- A fifth of users stopped taking the drug during the trial.
Zealand Pharma's stock experienced a significant decline, losing one-fifth of its value in Copenhagen trading. The company disclosed that a substantial number of participants, specifically one-fifth of users, discontinued its weight-loss drug during a trial. The primary reason cited for these discontinuations was the occurrence of gastrointestinal issues among users.